Hechtman 2011.

Methods	A patient report about a boy, who gets very emotional, with frequent crying, marked irritability and many tantrums when treated with methylphenidate. MPH use for around a year
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 5 years old IQ: > 70 Sex: male Ethnicity: not stated Country: Canada Comorbidity: oppositional defiant disorder and substantial learning disability in expressive and receptive language Comedication: not stated Sociodemographics: not stated
Interventions	OROS MPH dosage: 54 mg (the dosage was titrated from 36 mg to 54 mg) Administration schedule: once daily Duration of intervention: 1‐2 months Treatment compliance: not stated
Outcomes	Non‐serious adverse events: In late afternoon and early evening he became very emotional, with frequent crying, marked irritability and many tantrums. The emotional side effects subsided after he discontinued methylphenidate treatment
Notes	Funding/vested interests: Dr Hechtman declares having sat on the advisory boards/been a consultant for Eli Lilly, GlaxoSmithKline, Ortho Janssen, Purdue Pharma, and Shire Canada Comments from the study authors: children with ADHD often have other comorbid conditions that need to be addressed and treated, as stimulant medication is not likely to correct everything It is still unclear what predicts preferential response to 1 or the other stimulant. This preferential response should be kept in mind, so when children don't respond well to methylphenidate, the first change in medication should be to amphetamines Supplemental information regarding diagnostic criteria, type of ADHD and intervention period received through personal correspondence with the author in August 2013 (Hechtman 2013 [pers comm])